难治性急性白血病研究现状与进展

难治性急性白血病治疗反应差,诱导缓解率低,复发率高,生存期短,因而是白血病治疗中的难题。本文从难治性急性白血病诊断标准与免疫学、细胞遗传学及分子生物学特征,多药耐药与难治性白血病,难治性急性白血病治疗现状以及治疗展望五大方面阐述了难治性急性白血病研究现状与进展。基础与初步临床研究显示中药配合化疗能够提高难治性急性白血病围化疗期临床缓解率。认为中药在提高难治性白血病临床疗效方面具有潜在临床应用前景和开发的商业价值,值得进行深入研究。

The Progress and the Present of Patients with Refractory Acute Leukemia

In spite of continuous progress in the therapy of acute leukemia,relapses still occur frequently both in children and adults.A high incidence of relapses following induction chemotherapy is a major hindrance to patients' survival in acute leukemia.Refractory acute leukemia is almost invariably fatal and the treatment of patients with refractory or recurrent acute leukemia remains challenging.In this article,the progress in diagnostic criteria,immunology,cytogenetics,molecular biology,mul- tidrug resistance and therapy of refractory acute leukemia was summarized.Traditional Chinese medicine (TGM) plays an impor- tant role in the treatment of refractory acute leukemia,which,in combination with chemotherapy,can improve the remission rate for patients.The probability of relapse was reduced when patients had been assigned to be treated with TCM along with chemotherapy.The patients might particularly benefit from the procedure.Tberefore,it is believed that in clinical application and commercial development,TCM has a potential future,which is worth further studying.